Eyenovia, Inc. (NASDAQ:EYEN)
Industry: PharmaceuticalsMajor

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of hyperemia, pruritis, and dry eye; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

Current Quote*
Last: $2.946
Change: -0.054
Book: $4.699
Volume: 78,394

As Of: 10/22 12:52 ET
*Quotes delayed by 20min.

Graphs for EYEN

3 Month Graph

6 Month Graph

1 Year Graph